Visionary Holdings Secures Global License for Breakthrough Stem Cell Technology Targeting Diabetes Remission and Potential Cure
Toronto, October 13, 2025 — Visionary Holdings Inc. (Nasdaq: GV), a technology-driven multinational enterprise, today announced a landmark Global Product and Technology Licensing Agreement through its wholly owned subsidiary, Visionary Holdings (Asia) Limited. The agreement grants Visionary Holdings worldwide rights to apply an innovative stem cell technology developed by Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"), positioning the company at the forefront of regenerative medicine aimed at diabetes treatment.
A Major Leap in Diabetes Therapy
The licensed technology focuses on advanced stem cell therapies with demonstrated potential to achieve long-term remission and possibly complete cure for both Type 1 and Type 2 diabetes. Clinical trials conducted on Yike’s proprietary stem cell platform have exhibited groundbreaking results, restoring pancreatic islet function—a critical factor in diabetes management and remission.
Currently, diabetes affects over 540 million adults worldwide, with the global treatment market valued at more than USD 150 billion in 2024. Existing treatments primarily manage blood glucose levels and delay disease complications but fall short of offering a definitive cure. This breakthrough technology marks a significant advancement in shifting that paradigm.
Comprehensive Regenerative Medicine Approach
Beyond diabetes, the collaboration will explore applications of stem cell-based therapies in immune diseases, metabolic disorders, anti-aging biological repair, and cellular rejuvenation. The agreement includes the use of Yike’s integrated stem cell therapeutic technologies encompassing cell preparation, storage, quality control, and clinical application frameworks.
Strategic Global Commercialization and Collaboration
Visionary Holdings plans to leverage its extensive international commercialization network, clinical partnerships, and operational expertise to accelerate clinical application and market introduction of these life-transforming therapies on a global scale. The partnership operates under a revenue-sharing arrangement where Yike contributes scientific leadership and technology development, while Visionary Holdings takes charge of market-facing activities, including sales, branding, and business expansion.
Xiyong Hou, CEO of Visionary Holdings, stated, "This global license for Yike’s stem cell technology marks a major milestone in GV’s global health strategy. The technology’s potential to restore pancreatic islet function and achieve sustained diabetes remission offers hope to millions of patients worldwide. By integrating Yike’s cutting-edge regenerative science with GV’s global market capabilities, we are poised to deliver transformative medical solutions and drive significant revenue growth."
Future Plans and Industry Impact
Visionary Holdings and Yike intend to deepen their collaboration further through ongoing product research and development, clinical validations, and international market expansions. They also aim to jointly pursue global certification standards for regenerative medical products, thus setting a benchmark for the industry.
This partnership underscores Visionary Holdings’ commitment to pioneering advancements in medical technology and regenerative medicine to address some of the most pressing health challenges globally.
About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a Toronto-based multinational technology company specializing in innovative education, artificial intelligence applications, and advanced healthcare solutions. Operating through subsidiaries in North America and Asia, GV drives technological innovation and global health transformations.
For investor inquiries:
Visionary Holdings Inc. Investor Relations
Email: IR@visionary.holdings
Disclaimer: This announcement contains forward-looking statements subject to risks and uncertainties. Actual results may differ materially. Further details are available in filings with the U.S. Securities and Exchange Commission.
